Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
| Autor: | Annunziata Dattola, Nicoletta Bernardini, Giacomo Caldarola, Rosa Coppola, Clara De Simone, Domenico Giordano, Alessandro Giunta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Severino Persechino, Concetta Potenza, Federica Trovato, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Antonio Giovanni Richetta |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2160-9381 11664150 |
| DOI: | 10.5826/dpc.1403a166 |
| Popis: | Introduction: This was an observational, retrospective, multicenter study, enrolling elderly patients (>65 years old) treated with ixekizumab with a diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) during the period 2020 to 2023. Objectives: We sought to investigate the efficacy of ixekizumab in elderly patients in the treatment of moderate to severe psoriasis. Methods: We included 73 patients with psoriasis (32.9%), psoriatic arthritis (1.4%) and both of them (PsO-PsA 65.8%), attending the outpatient clinics of seven Italian referral center for psoriasis in Lazio region: Policlinico Umberto I Università Roma La Sapienza, Sant’Andrea Università di Roma La Sapienza, Polo Pontino Università Roma La Sapienza, Fondazione Policlinico Universitario A. Gemelli, Università Campus Biomedico Roma, Istituto Dermopatico dell’Immacolata, and Policlinico Tor Vergata. We collected data related to the characteristics of the patients (age, sex, body mass index) and of the disease (age at onset, duration of psoriasis, previous treatments). The severity of psoriasis was measured with the Psoriasis Area and Severity Index (PASI) score at baseline and after 16, 24, 52, 104 and 156 weeks of treatment. Results: PASI90 was achieved by all the patients in week 16 and remained stable until the end of the study. PASI100 has been achieved by 55.1% of patients at weeks 16 and by 81.3% at week 104. A statistically significant difference has been highlighted between baseline and all the other time points (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|